As the premier publisher of drug information, Facts & Comparisons TM provides a broad range of print and electronic resources to fulfill the day-to-day needs of practicing health care professionals. Drug Facts and Comparisons® (DFCJ, our flagship publication developed in 1946 by pharmacist Erwin K. Kastrup, was initially designed to provide objective information in a format that facilitated unbiased comparisons of drug products in a timely manner. After more than 60 years, the basic concepts remain the same. However, the content and presentation of material in DFC continues to evolve to reflect the changing needs of the health care environment.

Facts & Comparisons 4.0 also provides full monographs with complete prescribing information for nearly every single agent drug product, while the print versions continue to present abbreviated drug monographs in instances where a class monograph exists

The new 64th edition of DFC incorporates 21 new drugs: alvimopan (Entereg by GlaxoSmithKline), Cl inhibitor, human injection (Cinryze by Lev Pharmaceuticals), certolizumab pegol (Cimzia by UCB), clevidipine butyrate (Cleviprex by The Medicines Company), dexlansoprazole (Kapidex by Takeda Pharmaceuticals America), difluprednate (Durezol by Sirion Therapeutics), eltrombopag (Promacta by GlaxoSmithKline), everolimus (Afi nitor by Novartis Pharmaceuticals Company), febuxostat (Uloric by Takeda Pharmaceuticals America), fesoterodine fumarate (Toviaz by Pfizer), fibrinogen concentrate (human) injection (RiaSTAPby CSL), fospropofol disodium (Lusedra by Eisai), lacosamide (Vimpat by UCB), methylnaltrexonebromide (Relistor by Wyeth), milnacipran hydrochloride (Savella by Forest ), plerixafor (Mozobil by Genzyme), romiplostim (Nplate by Amgen), rufinamide (Banzel by Novartis Pharma AG), silodosin (Rapaflo by Watson Pharma), tetrabenazine (Xenazine by Prestwick),and valrubicin (Valstar by Indevus).

Download Volume 1 

Download Volume 1 


No comments:

Post a Comment